Özet:
The aim of this study was to investigate the effects of resveratrol against fumonisin B1
(FB1
)-induced liver toxicity, as, to the best of our
knowledge, these effects have not been investigated yet, even though the toxic effects and mechanisms of FB1
and the antioxidative effects
of resveratrol are well known. 40 BALB/c mice were divided into control, FB1
, resveratrol, and FB1
+resveratrol groups. Control received
saline for 14 days. The FB1
group received 2.25 mg/kg FB1
every other day for 14 days. The resveratrol group received 10 mg/kg resveratrol
for 14 days. The FB1
+resveratrol group received 2.25 mg/kg FB1
every other day and 10 mg/kg resveratrol every day for 14 days. All
administrations were peritoneal. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total sialic acid (TSA) levels were
analysed in serum samples, while total antioxidant status (TAS) and total oxidant status (TOS) were measured in the liver. Additionally,
the liver tissue was examined for histopathological changes. AST, ALT, and TSA were significantly higher in the FB1
group than control.
Resveratrol countered FB1
effects for all parameters, including TOS and TAS. Liver histology showed FB1
-induced hyperaemia, infiltrations,
and megalokaryosis in some hepatocytes. No pathological findings were detected in the control, resveratrol, or FB1
+resveratrol group.
Our findings confirm resveratrol’s protective effect against liver damage and oxidative stress caused by FB1
. In addition, they suggest that
increased serum TSA levels can be used as a biomarker of FB1
-induced hepatotoxicity
